Example: biology
Reflection Paper Expectations Electronic Source Data Data ...
At each stage of the electronic data capture and handling in the clinical trial database, the responsibilities of the investigator and the sponsor as defined in GCP should be applied, in order to ensure the reliability of the data. The use of electronic records for clinical data results in new issues as well as a need to reiterate
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Good Clinical Data Management Practices
www.bvv.sld.cuThe mission of the SCDM, promoting Clinical Data Management Excellence, includes promotion of standards of good practice within Clinical Data Management. In alignment with this part of the mission the SCDM Board of Trustees established a Committee to determine Standards for Good Clinical Data Management Practices (GCDMP) in 1998.
E 5 (R1) Ethnic Factors in the Acceptability of Foreign ...
www.ema.europa.euamount of clinical data in the new region in order to extrapolate or “bridge” the clinical data between the two regions. If a sponsor needs to obtain additional clinical data to fulfill the regulatory requirements of the new region, it is possible that these clinical trials can be designed to also serve as the bridging studies.
Australian clinical trial handbook
www.tga.gov.auClinical trials involving therapeutic goods are generally undertaken to assess the effects, efficacy, performance and/or safety of the product. It is therefore necessary that clinical trials are conducted using appropriate experimental designs to obtain valid data without exposing participants to unnecessary risks.
COVID-19 Infection Prevention and Control Manual …
www.cec.health.nsw.gov.auClinical Excellence Commission COVID-19 Infection Prevention and Control Manual Version 2.1 - 1 March 2022 Page 2 of 229 ... 1.6 Definitions 13 CHAPTER 2: INFECTION PREVENTION AND CONTROL STRATEGIES FOR COVID-19 16 Contents 16 Key points 17 Acronyms and abbreviations 17
Data Quality Management In Clinical Research
oir.nih.govThe data must be of sufficient quality and integrity to support the endpoint analyses The data used to support marketing applications for FDA-regulated research must be accurate and validated FDA E6 Good Clinical Practice (GCP) standards will be used as the basis of this course What you need to know:
Clinical Study Report (CSR) Template (Drug and Device)
clinicaltrials.govstatistical analyses of the efficacy and safety data outlined and/or specified in the final protocol of Study 1679-401-006 dated 23-Jun-2016. Specifications of tables, figures, and data listings are contained in a separate document. The SAP for pharmacokinetic (PK) data will be prepared separately. This document is organized into 3 main ...
ESR/2015/1571 Guideline: Clinical and related waste
environment.des.qld.gov.au2.1 Clinical waste Clinical waste means waste that has the potential to cause disease, including, for example, the following— (a) animal waste (b) discarded sharps (c) human tissue waste (d) laboratory waste. Clinical waste is prescribed category 1 regulated waste under the Environmental Protection Regulation 2019 (EP Regulation).